PARP1 and breast carcinoma: Mouse fibroblasts deficient in XRCC1 were hypersensitive to the PARP inhibitor 4-amino-1,8-naphthalimide (4-AN) [69], and XRCC1 knockdown breast cancer cells were hypersensitive to KU0058948 [70].